-
公开(公告)号：US06699843B2
公开(公告)日：2004-03-02
申请号：US09859724
申请日：2001-05-17
IPC分类号： A61K3170
CPC分类号： C40B50/04 , A61K38/00 , A61K47/544 , A61K47/547 , A61K47/549 , A61K47/60 , A61K48/00 , B82Y5/00 , C07H19/06 , C07H19/10 , C07H21/00 , C07K14/001 , C07K14/47 , C07K14/49 , C07K14/495 , C07K14/50 , C07K14/52 , C12N9/1276 , C12N15/1048 , C12N15/1136 , C12N15/115 , C12N2310/13 , C12N2310/317 , C12N2310/3183 , C12N2310/321 , C12N2310/322 , C12N2310/351 , C12N2310/3515 , C12N2310/53 , C12Q1/37 , C12Q1/6811 , C40B40/00 , F02B2075/027 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/56988 , G01N33/68 , G01N33/6842 , G01N33/76 , G01N2333/16 , G01N2333/163 , G01N2333/503 , G01N2333/575 , G01N2333/62 , G01N2333/8125 , G01N2333/96433 , G01N2333/96436 , G01N2333/96455 , G01N2333/96486 , G01N2333/966 , G01N2333/9726 , G01N2333/974 , G01N2333/976 , C12N2310/3521 , C12Q2525/101 , C12Q2525/301 , C12Q2541/101
摘要： A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.
摘要翻译： 提供了治疗实体瘤的方法，包括给予包含PDGF适体和细胞毒性剂的组合物。 在优选的实施方案中，使用SELEX方法鉴定了用于通过指数浓缩的配体的系统演化的PDGF适体。 还提供了用于降低实体瘤的组织液压（IFP）的方法，包括施用PDGF适体。 最后，提供了一种增加细胞毒剂到肿瘤中的摄取的方法，包括给予包含PDGF适体和细胞毒性剂的组合物。
-
2.发明授权Combination comprising a signal transduction inhibitor and an epothilone derivative 失效包含信号转导抑制剂和埃坡霉素衍生物的组合公开(公告)号：US07723339B2
公开(公告)日：2010-05-25
申请号：US10469367
申请日：2002-02-26
申请人： Ralf Brandt , Elisabeth Buchdunger , Carl-Henrik Heldin , Arne Östman , Kristian Pietras , Terence O'Reilly , John D Rothermel , Peter Traxler , Markus Wartmann
发明人： Ralf Brandt , Elisabeth Buchdunger , Carl-Henrik Heldin , Arne Östman , Kristian Pietras , Terence O'Reilly , John D Rothermel , Peter Traxler , Markus Wartmann
IPC分类号： A61K31/497 , A61K31/425 , A01N43/78 , A01N43/54 , C07D239/42 , C07D401/04 , A61K31/435 , A01N43/40 , A61K31/505
CPC分类号： A61K31/505 , A61K31/425 , A61K45/06 , A61K31/435 , A61K2300/00
摘要： The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.
摘要翻译： 本发明涉及包含N- {5- [4-（4-甲基 - 哌嗪子基 - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶胺和环硫代 衍生物; 包含所述组合的药物组合物; 包括所述组合的处理方法; 以及包括所述组合的商业包装。
-
3.发明申请Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor 审中-公开使用核酸配体治疗血小板衍生生长因子的肿瘤治疗方法和组合物公开(公告)号：US20070021327A1
公开(公告)日：2007-01-25
申请号：US11518321
申请日：2006-09-08
CPC分类号： C40B50/04 , A61K38/00 , A61K47/544 , A61K47/547 , A61K47/549 , A61K47/60 , A61K48/00 , B82Y5/00 , C07H19/06 , C07H19/10 , C07H21/00 , C07K14/001 , C07K14/47 , C07K14/49 , C07K14/495 , C07K14/50 , C07K14/52 , C12N9/1276 , C12N15/1048 , C12N15/1136 , C12N15/115 , C12N2310/13 , C12N2310/317 , C12N2310/3183 , C12N2310/321 , C12N2310/322 , C12N2310/351 , C12N2310/3515 , C12N2310/53 , C12Q1/37 , C12Q1/6811 , C40B40/00 , F02B2075/027 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/56988 , G01N33/68 , G01N33/6842 , G01N33/76 , G01N2333/16 , G01N2333/163 , G01N2333/503 , G01N2333/575 , G01N2333/62 , G01N2333/8125 , G01N2333/96433 , G01N2333/96436 , G01N2333/96455 , G01N2333/96486 , G01N2333/966 , G01N2333/9726 , G01N2333/974 , G01N2333/976 , C12N2310/3521 , C12Q2525/101 , C12Q2525/301 , C12Q2541/101
摘要： A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.
摘要翻译： 提供了治疗实体瘤的方法，包括给予包含PDGF适体和细胞毒性剂的组合物。 在优选的实施方案中，使用SELEX方法鉴定使用指数浓缩的配体系统演化的PDGF适体。 还提供了用于降低实体瘤的组织液压（IFP）的方法，包括施用PDGF适体。 最后，提供了一种增加细胞毒剂到肿瘤中的摄取的方法，包括给予包含PDGF适体和细胞毒性剂的组合物。
-
4.发明授权Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor 有权使用核酸配体治疗血小板衍生生长因子的肿瘤治疗方法和组合物公开(公告)号：US07141375B2
公开(公告)日：2006-11-28
申请号：US10791367
申请日：2004-03-02
CPC分类号： C40B50/04 , A61K38/00 , A61K47/544 , A61K47/547 , A61K47/549 , A61K47/60 , A61K48/00 , B82Y5/00 , C07H19/06 , C07H19/10 , C07H21/00 , C07K14/001 , C07K14/47 , C07K14/49 , C07K14/495 , C07K14/50 , C07K14/52 , C12N9/1276 , C12N15/1048 , C12N15/1136 , C12N15/115 , C12N2310/13 , C12N2310/317 , C12N2310/3183 , C12N2310/321 , C12N2310/322 , C12N2310/351 , C12N2310/3515 , C12N2310/53 , C12Q1/37 , C12Q1/6811 , C40B40/00 , F02B2075/027 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/56988 , G01N33/68 , G01N33/6842 , G01N33/76 , G01N2333/16 , G01N2333/163 , G01N2333/503 , G01N2333/575 , G01N2333/62 , G01N2333/8125 , G01N2333/96433 , G01N2333/96436 , G01N2333/96455 , G01N2333/96486 , G01N2333/966 , G01N2333/9726 , G01N2333/974 , G01N2333/976 , C12N2310/3521 , C12Q2525/101 , C12Q2525/301 , C12Q2541/101
摘要： A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.
摘要翻译： 提供了治疗实体瘤的方法，包括给予包含PDGF适体和细胞毒性剂的组合物。 在优选的实施方案中，使用SELEX方法鉴定了用于通过指数浓缩的配体的系统演化的PDGF适体。 还提供了用于降低实体瘤的组织液压（IFP）的方法，包括施用PDGF适体。 最后，提供了一种增加细胞毒剂到肿瘤中的摄取的方法，包括给予包含PDGF适体和细胞毒性剂的组合物。
-
公开(公告)号：US06974816B2
公开(公告)日：2005-12-13
申请号：US10227081
申请日：2002-08-23
CPC分类号： A61K48/0008
摘要： The invention relates to a combination of (a) an inhibitor of platelet-derived growth factor (PDGF) activity and (b) a vector for vascular endothelial growth factor (VEGF-, especially VEGF-C) gene transfer, a pharmaceutical preparation comprising (a) and (b) in combination together with a pharmaceutically acceptable carrier material; a product comprising (a) and (b) as defined above and optionally a pharmaceutically acceptable carrier material, for simultaneous, chronologically staggered or separate use; a method of administering or the use of said combination or product for the treatment of endothelial damage; and/or to the use of (a) and (b) for the manufacture of said pharmaceutical preparation or product for the treatment of endothelial damage.
摘要翻译： 本发明涉及（a）血小板衍生生长因子（PDGF）活性抑制剂和（b）血管内皮生长因子（VEGF-，特别是VEGF-C）基因转移载体的组合，包含（ a）和（b）与药学上可接受的载体材料的组合; 包含如上定义的（a）和（b）和任选的药学上可接受的载体材料的产品，用于同时，按时间顺序交错或分开使用; 施用或使用所述组合或产品来治疗内皮损伤的方法; 和/或（a）和（b）用于制造用于治疗内皮损伤的所述药物制剂或产品的用途。
-
6.发明申请公开(公告)号：US20140140998A1
公开(公告)日：2014-05-22
申请号：US14004490
申请日：2012-03-13
申请人： Marene Inga-Britt Landstrom , Yabing Mu , Reshma Sundar , Noopur Thakur , Shyam Kumar Gudey , Maria Ekman , Carl-Henrik Heldin
发明人： Marene Inga-Britt Landstrom , Yabing Mu , Reshma Sundar , Noopur Thakur , Shyam Kumar Gudey , Maria Ekman , Carl-Henrik Heldin
CPC分类号： C07K16/2863 , A61K31/00 , A61K31/4709 , A61K31/65 , A61K39/395 , C07K14/71 , C07K2317/34 , C07K2317/70 , C12Q1/686 , G01N33/57496 , G01N2333/495
摘要： Disclosed herein are methods to inhibit cleavage of a type I receptor of transforming growth factor beta (TβRI) and reduce cancer cell invasiveness/metastasis, and agents and pharmaceutical compositions for use in these methods. Also disclosed herein are methods for identifying agents that inhibit cleavage of TβRI and methods for diagnosing and/or prognosing cancer based on nuclear localization of a intracellular domain of TβRI, which is a product of TβRI cleavage.
-
公开(公告)号：US06982319B2
公开(公告)日：2006-01-03
申请号：US09903068
申请日：2001-07-11
摘要： A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-β-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIB and/or a GTKRYM sequence in subdomain VIII.
摘要翻译： 已经鉴定了激活素样激酶的新受体家族。 新型蛋白质具有激活素/ TGF-β-I受体功能，并具有相应的诊断/治疗效用。 它们可以具有丝氨酸/苏氨酸激酶结构域，子域VIB中的DFKSRN或DLKSKN序列和/或亚域VIII中的GTKRYM序列。
-
公开(公告)号：US20050136043A1
公开(公告)日：2005-06-23
申请号：US10911414
申请日：2004-08-04
CPC分类号： C07K14/4702 , A61K38/00
摘要： This invention relates to peptide molecules and compounds which are negative regulators of TGFβ signaling, particularly of TβR-I kinase activity. The invention further relates to methods of using such peptides and compounds in the treatment of disease.
摘要翻译： 本发明涉及作为TGFbeta信号传导的负调节剂的肽分子和化合物，特别是TbetaR-1激酶活性。 本发明还涉及使用这些肽和化合物治疗疾病的方法。
-
9.发明授权
公开(公告)号：US06066472A
公开(公告)日：2000-05-23
申请号：US100804
申请日：1998-06-19
IPC分类号： C12N15/09 , C07K16/40 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/16 , C12N15/55 , C12P21/08 , C12Q1/68 , C12N15/52 , C12N15/63
摘要： The invention relates to the cloning of two novel protein tyrosine phosphatases. Nucleic acid sequences encoding these phosphatases (PTPL1 and GLM-2) as well as anti-sense sequences are also provided. The recombinantly produced PTPL1 and GLM-2 proteins also are provided, as well as antibodies to these proteins. Methods relating to isolating the phosphatases, using the nucleic acid sequences, and using the phosphatases also are provided.
摘要翻译： 本发明涉及两种新型蛋白酪氨酸磷酸酶的克隆。 还提供了编码这些磷酸酶（PTPL1和GLM-2）的核酸序列以及反义序列。 还提供重组产生的PTPL1和GLM-2蛋白质，以及对这些蛋白质的抗体。 还提供了使用核酸序列和使用磷酸酶分离磷酸酶的方法。
-
公开(公告)号：US5821075A
公开(公告)日：1998-10-13
申请号：US596291
申请日：1996-08-09
IPC分类号： C12N15/09 , C07K16/40 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/16 , C12N15/55 , C12P21/08 , C12Q1/68 , C12Q1/42 , C07K14/435
摘要： The invention relates to the cloning of two novel protein tyrosine phosphatases. Nucleic acid sequences encoding these phosphatases (PTPL1 and GLM-2) as well as anti-sense sequences are also provided. The recombinantly produced PTPL1 and GLM-2 proteins also are provided, as well as antibodies to these proteins. Methods relating to isolating the phosphatases, using the nucleic acid sequences, and using the phosphatases also are provided.
摘要翻译： PCT No.PCT / US94 / 09943 Sec。 371日期：1996年8月9日 102（e）日期1996年8月9日PCT提交1994年9月1日PCT公布。 公开号WO95 / 06735 日期1995年3月9日本发明涉及两种新型蛋白酪氨酸磷酸酶的克隆。 还提供了编码这些磷酸酶（PTPL1和GLM-2）的核酸序列以及反义序列。 还提供重组产生的PTPL1和GLM-2蛋白质，以及对这些蛋白质的抗体。 还提供了使用核酸序列和使用磷酸酶分离磷酸酶的方法。
-
-
-
-
-
-
-
-
-
搜索结果
51 条记录 (耗时 0.036 秒)
